Novel Gene Signatures Promote Epithelial-Mesenchymal Transition (EMT) in Glucose Deprivation-Based Microenvironment to Predict Recurrence‐Free Survival in Hepatocellular Carcinoma. (21st February 2023)
- Record Type:
- Journal Article
- Title:
- Novel Gene Signatures Promote Epithelial-Mesenchymal Transition (EMT) in Glucose Deprivation-Based Microenvironment to Predict Recurrence‐Free Survival in Hepatocellular Carcinoma. (21st February 2023)
- Main Title:
- Novel Gene Signatures Promote Epithelial-Mesenchymal Transition (EMT) in Glucose Deprivation-Based Microenvironment to Predict Recurrence‐Free Survival in Hepatocellular Carcinoma
- Authors:
- Huang, Yuan
Li, Shi-Rong
Gao, Ying-Jie
Zhu, Yan-hua
Zhang, Xiao-feng - Other Names:
- Qin Shuanglin Academic Editor.
- Abstract:
- Abstract : Background . Current research studies have suggested that glucose deprivation (GD)-based tumor microenvironment (TME) can promote epithelial-mesenchymal transition (EMT) of tumor cells, leading to tumor invasion and metastasis. However, no one has yet studied detailedly the synthetic studies that include GD features in TME with EMT status. In our research, we comprehensively developed and validated a robust signature regarding GD and EMT status to provide prognostic value for patients with liver cancer. Methods . GD and EMT status were estimated with transcriptomic profiles based on WGCNA and t-SNE algorithms. Two cohorts of training (TCGA_LIHC) and validation (GSE76427) datasets were analyzed with the Cox regression and logistic regression analyses. We identified a 2-mRNA signature to establish a GD-EMT-based gene risk model for the prediction of HCC relapse. Results . Patients with significant GD-EMT status were divided into two subgroups: GD low /EMT low and GD high /EMT high, with the latter having significantly worse recurrence-free survival (P < 0.01 ). We employed the least absolute shrinkage and selection operator (LASSO) technique as a method for HNF4A and SLC2A4 filtering and constructing a risk score for risk stratification. In the multivariate analysis, this risk score predicted recurrence-free survival (RFS) in both the discovery and validation cohorts and remained valid in patients stratified by TNM stage and age at diagnosis. The nomogram thatAbstract : Background . Current research studies have suggested that glucose deprivation (GD)-based tumor microenvironment (TME) can promote epithelial-mesenchymal transition (EMT) of tumor cells, leading to tumor invasion and metastasis. However, no one has yet studied detailedly the synthetic studies that include GD features in TME with EMT status. In our research, we comprehensively developed and validated a robust signature regarding GD and EMT status to provide prognostic value for patients with liver cancer. Methods . GD and EMT status were estimated with transcriptomic profiles based on WGCNA and t-SNE algorithms. Two cohorts of training (TCGA_LIHC) and validation (GSE76427) datasets were analyzed with the Cox regression and logistic regression analyses. We identified a 2-mRNA signature to establish a GD-EMT-based gene risk model for the prediction of HCC relapse. Results . Patients with significant GD-EMT status were divided into two subgroups: GD low /EMT low and GD high /EMT high, with the latter having significantly worse recurrence-free survival (P < 0.01 ). We employed the least absolute shrinkage and selection operator (LASSO) technique as a method for HNF4A and SLC2A4 filtering and constructing a risk score for risk stratification. In the multivariate analysis, this risk score predicted recurrence-free survival (RFS) in both the discovery and validation cohorts and remained valid in patients stratified by TNM stage and age at diagnosis. The nomogram that combines risk score and TNM stage as well as age produces improved performance and net benefits in the analysis of calibration and decision curves in training and validation groups. Conclusions . The GD-EMT-based signature predictive model may provide a prognosis classifier for HCC patients with a high risk of postoperative recurrence to decrease the relapse rate. … (more)
- Is Part Of:
- Journal of oncology. Volume 2023(2023)
- Journal:
- Journal of oncology
- Issue:
- Volume 2023(2023)
- Issue Display:
- Volume 2023, Issue 2023 (2023)
- Year:
- 2023
- Volume:
- 2023
- Issue:
- 2023
- Issue Sort Value:
- 2023-2023-2023-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-02-21
- Subjects:
- Oncology -- Research -- Periodicals
Tumors -- Periodicals
Neoplasms
Oncology -- Research
Tumors
Periodicals
Periodicals
616.994 - Journal URLs:
- https://www.hindawi.com/journals/jo/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=859&action=archive ↗ - DOI:
- 10.1155/2023/6114976 ↗
- Languages:
- English
- ISSNs:
- 1687-8450
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 26130.xml